Insilico Medicine Reports First Human Dosing of ISM8969
HONG KONG, June 18, 2026 Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence (AI), has announced...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
HONG KONG, June 18, 2026 Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence (AI), has announced...
